<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6481">
  <stage>Registered</stage>
  <submitdate>23/11/2016</submitdate>
  <approvaldate>23/11/2016</approvaldate>
  <nctid>NCT02974868</nctid>
  <trial_identification>
    <studytitle>Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata</studytitle>
    <scientifictitle>A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study With An Extension Period To Evaluate The Efficacy And Safety Profile Of Pf-06651600 And Pf-06700841 In Subjects With Moderate To Severe Alopecia Areata</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-004048-13</secondaryid>
    <secondaryid>B7931005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alopecia Areata</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Other skin conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PF-06651600
Treatment: drugs - PF-06700841
Treatment: drugs - Placebo

Experimental: Cohort 1 - PF-06651600

Experimental: Cohort 2 - PF-06700841

Placebo Comparator: Cohort placebo - placebo


Treatment: drugs: PF-06651600
200 mg QD during induction and 50 mg QD during Maintenance

Treatment: drugs: PF-06700841
60 mg QD during induction and 30 mg QD during maintenance

Treatment: drugs: Placebo
Placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline of Severity of Alopecia Tool (SALT) score at Week 24. - assessment of the overall severity of alopecia areata</outcome>
      <timepoint>baseline, 24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of treatment emergent adverse events (AEs) during the Extension Period</outcome>
      <timepoint>Baseline of extension period (Week 28) up to 12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of specific clinical laboratory abnormalities including but not limited to anemia, neutropenia, thrombocytopenia, lymphopenia, changes in lipid profile, and liver function tests (LFTs) during the Extension Period</outcome>
      <timepoint>Baseline of extension period (Week 28) up to 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving a 30% improvement in SALT (SALT 30) at Week 24 - overall assessment of severity of AA</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Investigator Global Assessment (IGA) - overall severity of AA</outcome>
      <timepoint>baseline, 32 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in SALT - overall severity of AA</outcome>
      <timepoint>baseline, 32 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving a 30% improvement in SALT (SALT 30) - severity of AA</outcome>
      <timepoint>32 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving a 50% improvement in SALT (SALT 50) - severity of AA</outcome>
      <timepoint>32 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage change in SALT from baseline to Week 24 - severity of AA</outcome>
      <timepoint>baseline, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving a 75% improvement in SALT (SALT 75) - severity of AA</outcome>
      <timepoint>32 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects achieving a 100% improvement in SALT (SALT 100) - severity of AA</outcome>
      <timepoint>32 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of treatment emergent adverse events (AEs) up to Week 24</outcome>
      <timepoint>Day 1 to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of specific clinical laboratory abnormalities including but not limited to anemia, neutropenia, thrombocytopenia, lymphopenia, changes in lipid profile, and liver function tests (LFTs) up to Week 24</outcome>
      <timepoint>Day 1 to week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female subjects between 18 75 years of age, inclusive, at time of informed
             consent.

          -  Must have moderate to severe alopecia areata:</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of human immunodeficiency virus (HIV) or positive HIV serology at screening,

          -  Infected with hepatitis B or hepatitis C viruses.

          -  Have evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis (TB)

          -  Have received any of the following treatment regiments specified in the timeframes
             outlined below:

        Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of
        first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks
        of first dose of study drug: Participation in other studies involving investigational
        drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or
        attenuated live vaccine.

        Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy
        (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning
        booth/parlor.

        Within 2 week of first dose of study drug: Topical treatments that could affect AA; Herbal
        medications with unknown properties or known beneficial effects for AA.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>15/12/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>132</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>12/05/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>St George Dermatology and Skin Cancer Centre - Kogarah</hospital>
    <hospital>The Skin Centre - Benowa</hospital>
    <hospital>Veracity Clinical Research - Woolloongabba</hospital>
    <hospital>Skin &amp; Cancer Foundation Inc. - Carlton</hospital>
    <hospital>Sinclair Dermatology - East Melbourne</hospital>
    <postcode>2217 - Kogarah</postcode>
    <postcode>4217 - Benowa</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3053 - Carlton</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an
      extension period. The study will have a maximum duration of approximately 85 weeks. This
      includes an up to 5 weeks screening period, a 24 week treatment period, a 4 week drug
      holiday, an up to 12 month extension period, and a 4 week follow up period. The study will
      enroll a total of approximately 132 subjects. The study will be conducted at approximately 30
      to 40 sites.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02974868</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address />
      <phone>1-800-718-1021</phone>
      <fax />
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>